Initial group of patients have received Saphnelo in a phase 3 trial evaluating lupus nephritis
News
NICE recommendation for Sanofi and Regeneron’s CSCC treatment
Libtayo has been approved for adults when curative surgery or radiation is not appropriate
EC approves Janssen T-cell therapy for multiple myeloma treatment
Approval provides another step forward in transforming multiple myeloma outcomes and eliminating the disease
Cumulus Neuroscience begins studies of digital biomarker
Technology is already being used in clinical trials of new treatments for Alzheimer’s and new studies will provide additional validation
Pfizer/BioNTech vaccine effective against Omicron in children five and under
Companies say that three-dose vaccine for children aged six months to five years old is 80% effective at preventing illness
Alternative to open heart surgery emerges following NIHR research
Less invasive procedure offers an equally effective alternative for heart condition patients
PTC Therapeutic’s Upstaza has been recommended by both the EMA and CHMP
It is the first gene therapy to be directly administered into the brain to treat aromatic L-amino acid decarboxylase (AADC) deficiency
CHMP recommends Sanofi’s Xenpozyme for rare disease ASMD
Positive opinion is based on data from clinical trials which showed improvement in lung function
NICE recommends app-based treatment for insomnia over sleeping pills
Thousands usually prescribed sleeping pills could be offered app-based treatment
Birmingham research shows promise for spinal cord injury patients
Scientists demonstrated that AZD1236 halts oedema while reducing spinal cord breakdown at site of injury
Simple blood test could save thousands from bowel cancer
Comparisons with other tests available have shown that blood test has greater sensitivity for the detection of bowel cancer
The Baillie Gifford Pandemic Science Hub launched to fight lung disease
Gifford is supporting the launch with a philanthropic donation of £14.7m
Curebase and Flow Neuroscience launch clinical trial to test at-home headset for depression
Device delivers currents to the brain to restore activity usually lowered in depression patients
EpiEndo successfully completes phase 1 study into respiratory treatment
Orally available EP395 has met all endpoints in safety and is now undergoing phase 2 planning
MHRA marketing authorisation granted for Eli Lilly’s Verzenios as early breast cancer treatment
Authorisation of the treatment is based on results from the phase 3 trial
